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Abstract
Cytotoxic T-lymphocytes play an important role in the protection against viral infections, which they detect through the
recognition of virus-derived peptides, presented in the context of MHC class I molecules at the surface of the infected cell.
The transporter associated with antigen processing (TAP) plays an essential role in MHC class I–restricted antigen
presentation, as TAP imports peptides into the ER, where peptide loading of MHC class I molecules takes place. In this study,
the UL49.5 proteins of the varicelloviruses bovine herpesvirus 1 (BHV-1), pseudorabies virus (PRV), and equine herpesvirus 1
and 4 (EHV-1 and EHV-4) are characterized as members of a novel class of viral immune evasion proteins. These UL49.5
proteins interfere with MHC class I antigen presentation by blocking the supply of antigenic peptides through inhibition of
TAP. BHV-1, PRV, and EHV-1 recombinant viruses lacking UL49.5 no longer interfere with peptide transport. Combined with
the observation that the individually expressed UL49.5 proteins block TAP as well, these data indicate that UL49.5 is the viral
factor that is both necessary and sufficient to abolish TAP function during productive infection by these viruses. The
mechanisms through which the UL49.5 proteins of BHV-1, PRV, EHV-1, and EHV-4 block TAP exhibit surprising diversity.
BHV-1 UL49.5 targets TAP for proteasomal degradation, whereas EHV-1 and EHV-4 UL49.5 interfere with the binding of ATP
to TAP. In contrast, TAP stability and ATP recruitment are not affected by PRV UL49.5, although it has the capacity to arrest
the peptide transporter in a translocation-incompetent state, a property shared with the BHV-1 and EHV-1 UL49.5. Taken
together, these results classify the UL49.5 gene products of BHV-1, PRV, EHV-1, and EHV-4 as members of a novel family of
viral immune evasion proteins, inhibiting TAP through a variety of mechanisms.
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Introduction
Evolving under the selective pressure of the host immune
system, herpesviruses have developed countermeasures to prevent
recognition of infected cells by cytotoxic CD8+ T lymphocytes
(CTLs). CTLs recognize viral antigens presented as peptides
bound to major histocompatibility complex (MHC) class I
molecules at the surface of infected cells. Herpesviruses in
particular have acquired diverse mechanisms to inhibit antigen
presentation in the context of MHC class I molecules, thereby
escaping from elimination by CTLs [1–4].
Most peptides presented by MHC class I molecules are
transported into the endoplasmic reticulum (ER) lumen by the
transporter associated with antigen processing, TAP. TAP is a
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heterodimer composed of TAP1 and TAP2 subunits and belongs
to the ATP-binding cassette family of transporters [5,6]. TAP
translocates peptides across the ER membrane via a conforma-
tional transition that is energized by the hydrolysis of ATP. TAP is
part of the MHC class I peptide-loading complex that also
contains tapasin, MHC class I heavy and light chains, and several
auxiliary proteins including calreticulin and ERp57 [5,7–10].
Several herpesviruses have acquired mechanisms to interfere
with TAP function. Interestingly, inhibition of TAP transport is
achieved through different strategies, exerted by unique gene
products. Although the varicellovirus bovine herpesvirus 1 (BHV-
1) and the simplexviruses herpes simplex virus type 1 and 2 (HSV-
1 and -2) all belong to the subfamily of alphaherpesviruses, they
block TAP through proteins that have an entirely different
structure and mode of action. The inhibition of TAP by BHV-1
relies on the UL49.5 (Unique Long 49.5) gene product, a type I
transmembrane protein of 75 amino acids [11]. Inactivation of
TAP by UL49.5 involves two events: the arrest of the peptide
transporter in a translocation-incompetent state and the protea-
somal degradation of both subunits of TAP [11]. In contrast, the
ICP47 proteins of HSV-1 and -2 are soluble cytosolic proteins
acting as high-affinity competitors for peptide binding to TAP
[12–18]. Within the subfamily of betaherpesviruses, human
cytomegalovirus (HCMV) was found to encode a protein, US6,
that inhibits TAP function by reducing the interaction of ATP
with TAP [19–24]. The murine gammaherpesvirus-68 (MHV-68)
encodes the mK3 protein that acts as a ubiquitin ligase linking
MHC class I molecules and TAP to the ubiquitin/proteasome
degradation pathway [25–35]. Recently, the BNLF2a protein of
Epstein-Barr virus (EBV) and of related primate gamma-1
herpesviruses has been characterized as a potent TAP inhibitor,
preventing the binding of both peptides and ATP to TAP [36].
Homologs of UL49.5 (commonly known as glycoprotein N; gN)
are encoded by every alpha-, beta- and gammaherpesvirus
sequenced to date [37–39]. The UL49.5 genes are all predicted to
encode a type I membrane protein with a putative cleavable signal
sequence. The UL49.5 proteins interact with another herpesvirus
protein, glycoprotein M (gM), with which they form a disulfide-
linked heterodimer through a conserved cysteine residue within their
ER-luminal/extracellular domain [37,40–44]. Nevertheless, the
amino acid sequences of UL49.5 proteins demonstrate considerable
heterogeneity, even among varicellovirus UL49.5 proteins (Fig. 1).
The only exceptions are EHV-1 and EHV-4 UL49.5, which differ
by only seven amino acid residues. Thus, at this moment, it is
impossible to predict on the basis of amino acid sequence whether
any of these proteins have the same capacity to inhibit TAP that was
found for BHV-1 UL49.5. The UL49.5 gene products of HSV-1,
HSV-2, HCMV, and EBV fail to block TAP, indicating that not all
UL49.5 molecules act as inhibitors of TAP [11,37].
In this study, the effects on TAP function were assessed in more
detail for UL49.5 encoded by various members of the genus
Varicellovirus. The UL49.5 proteins of BHV-1, PRV, EHV-1, and
EHV-4 were found to down-regulate MHC class I cell surface
expression through TAP inhibition. Their ability to block TAP
was observed in cells of the relevant host species, as well as in
human cells. Using UL49.5 deletion mutants of BHV-1, PRV and
EHV-1, it was shown that the UL49.5 proteins of these viruses are
responsible for the inhibition of TAP-dependent peptide transport.
The UL49.5 homologs of canine herpesvirus (CHV) and VZV did
not affect MHC class I surface expression. BHV-1 UL49.5
strongly reduces the steady state protein levels of TAP in both
bovine and human cells, whereas the UL49.5 proteins of EHV-1,
EHV-4 or PRV were not observed to have this capacity.
Interestingly, the EHV-1 and EHV-4 UL49.5 homologs interfere
with the binding of ATP to TAP, a function that is not influenced
by BHV-1 or PRV UL49.5. The UL49.5 proteins of PRV and
Author Summary
Herpesviruses have the conspicuous property that they
persist for life in the infected host. This is also the case for
varicelloviruses, a large subfamily of herpesviruses with
representatives in humans (varicella zoster virus or VZV),
cattle (bovine herpesvirus 1 or BHV-1), pigs (pseudorabies
virus or PRV), and horses (equine herpesvirus or EHV type 1
and 4), among many others. Cytotoxic T-lymphocytes play
an important role in the protection against viral infections,
which they detect through the recognition of virus-derived
peptides, presented in the context of MHC class I
molecules at the surface of the infected cell. The
transporter associated with antigen processing (TAP) plays
an essential role in this process, as TAP imports peptides
into the compartment where peptide loading of the MHC
class I molecules takes place. In this study, we show that
the UL49.5 proteins of BHV-1, PRV, EHV-1, and EHV-4 all
block the supply of peptides through the inhibition of TAP,
but that the mechanisms employed by these proteins to
inhibit TAP function exhibit surprising diversity. VZV
UL49.5, on the other hand, binds to TAP, but does not
interfere with peptide transport. Our study classifies the
UL49.5 proteins of BHV-1, PRV, EHV-1, and EHV-4 as
members of a novel family of viral immune evasion
proteins, inhibiting TAP through a variety of mechanisms.
Figure 1. Alignment of the amino acid sequences of UL49.5 homologs of a selection of alphaherpesviruses (NCBI accession
numbers are summarized in Materials and Methods). Hydrophobic residues indicative of N-terminal signal sequences (dashed line) and
membrane anchor regions (bold line) are indicated. The conserved cysteine residue involved in disulfide bond formation with the viral glycoprotein
M is indicated. The amino acid sequence alignment of UL49.5 homologs was performed using VectorNTI software (Invitrogen).
doi:10.1371/journal.ppat.1000080.g001
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EHV-1 arrest TAP in a translocation-incompetent state, a
property that is shared with BHV-1 UL49.5. Thus, the BHV-1,
PRV, EHV-1 and EHV-4-encoded UL49.5 proteins all induce a
similar phenotype, i.e. inhibition of peptide transport, but their
modes of action demonstrate a surprising diversity.
Results
Inhibition of TAP by UL49.5 proteins of varicelloviruses
To evaluate the TAP-inhibiting capacity of the UL49.5 proteins
encoded by the varicelloviruses PRV, EHV-1, EHV-4, CHV and
VZV, cell lines of the relevant host species were transduced using a
retrovirus-based gene delivery system to express the corresponding
UL49.5 proteins. Down-regulation of MHC class I expression by
the UL49.5 gene products was evaluated using flow cytometry. In
cells expressing UL49.5 of BHV-1, PRV, EHV-1 and EHV-4,
MHC class I surface expression was reduced (Fig. 2A). The
UL49.5 proteins of CHV and VZV failed to down-regulate MHC
class I surface expression. These results indicate that UL49.5 of
BHV-1, PRV, EHV-1 and EHV-4 interfere with MHC class I-
restricted antigen presentation.
To investigate whether the observed down-regulation of MHC
class I cell surface expression relies on the inhibition of TAP,
species-specific cell lines stably expressing these UL49.5 homologs
were evaluated for TAP-dependent peptide transport. The
UL49.5 proteins of BHV-1, PRV, EHV-1 and EHV-4 strongly
inhibited TAP activity in the corresponding natural host cell lines
(Fig. 2B). Despite the absence of a detectable reduction in cell
surface MHC class I levels (Fig. 2A), some inhibition of TAP-
dependent peptide transport was observed in canine cells
expressing the CHV UL49.5 protein (Fig. 2B). Apparently, the
inhibition of TAP by CHV UL49.5 was insufficient to observe
MHC class I downregulation at the cell surface. VZV UL49.5 had
no significant effect on TAP activity. Thus, although the amino
acid sequences of the UL49.5 proteins of BHV-1, PRV, and EHV-
1/EHV-4 demonstrate considerable variation (Fig. 1), their ability
to inhibit TAP was found to be a common property of these
varicellovirus gene products.
The interaction of VZV UL49.5 with the peptide-loading
complex has no functional consequences for MHC class I-
restricted antigen presentation
VZV infection has been shown to cause down-regulation of
MHC class I expression at the cell surface [45–47]. This
phenotype could not be reproduced by the VZV-encoded
UL49.5 protein when expressed individually (Fig. 2A). To examine
whether the absence of MHC class I down-regulation by VZV
UL49.5 is due to a loss of the interaction of the viral protein with
the TAP complex, TAP was immunoprecipitated from VZV
UL49.5-expressing MJS cells that were solubilized in the presence
of the mild detergent digitonin. The resulting protein complexes
were separated by SDS PAGE and analyzed for the presence of
Figure 2. TAP inhibition by Varicellovirus-encoded UL49.5 homologs in natural host cells. (A) MHC class I expression in cells from the
relevant host species stably expressing the UL49.5 homologs of BHV-1, PRV, EHV-1, EHV-4, CHV and VZV. Cells of bovine (MDBK), porcine (PK15),
equine (E.derm), canine (MDCK), and human origin (MJS) were transduced with retroviruses expressing the respective UL49.5 proteins. Surface MHC
class I molecules were stained with specific antibodies and analyzed using flow cytometry. Shown are the MHC class I levels on cells without UL49.5
(thin line) and with UL49.5 (boldface line); dashed line, goat anti-mouse phycoerythrin control. (B) TAP-dependent peptide transport is inhibited in
cells from the relevant host species expressing BHV-1, PRV, EHV-1, EHV-4 and CHV UL49.5, but not in MJS cells expressing VZV UL49.5. Peptide
transport was assessed in the presence and absence of ATP (black and open bars, respectively). Peptide transport is expressed as percentage of
translocation, relative to the translocation observed in control cells (defined as 100%). The standard deviations are represented by the error bars. A
difference at p,0.05 was considered significant.
doi:10.1371/journal.ppat.1000080.g002
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UL49.5 by immunoblotting. Surprisingly, VZV UL49.5 was found
to interact with the TAP complex (Fig. 3A).
Although VZV UL49.5 associates with TAP, this appears to be
insufficient to inhibit peptide transport effectively (Fig. 2A and B).
VZV UL49.5 could, however, interfere with peptide-loading and
MHC class I-restricted antigen presentation in a different way. For
instance, the US3 protein encoded by human cytomegalovirus
binds both tapasin and TAP, without having an effect on TAP
function. Instead, US3 impairs tapasin-dependent peptide loading
and optimization of the MHC class I peptide cargo [48,49]. To
investigate whether VZV UL49.5 inhibits MHC class I-mediated
antigen presentation via a mechanism similar to that of US3,
Figure 3. VZV UL49.5 interacts with the peptide-loading complex, but does not inhibit MHC class I-restricted T cell recognition. (A)
TAP1 was immunoprecipitated (IP) from MJS cells expressing EHV-1 or VZV UL49.5 proteins. Co-precipitating UL49.5 proteins were analyzed by
immunoblotting (IB) using antibodies against EHV-1 or VZV UL49.5. Left panel: cell lysates were loaded on SDS-PAGE directly and stained by
immunoblotting. (B) BHV-1 or VZV UL49.5-expressing PHA-treated T-cell blasts were labeled with 51Cr and used as target cells for CTL clones specific
for the minor histocompatibility antigens HY and HA-2, recognized in the context of HLA-A1 and HLA-A2, respectively. Specific lysis was determined
by measuring 51Cr release from the target cells after 4 hrs. Effector/target (E/T) ratios are indicated. (C) PHA-treated T-cell blasts or a melanoma cell
line (Mel518) carrying the HY antigen were incubated with the HY-specific CTL clone HY HLA-A1. IFN-c levels released by the CTL clones were
determined from the supernatants of the co-cultures after 24 hrs.
doi:10.1371/journal.ppat.1000080.g003
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functional T cell assays were performed using a panel of human
leukocyte antigen (HLA)-A1 and HLA-A2-restricted CTL clones.
It is known that especially HLA-A1-restricted peptide presentation
strongly depends on the function of tapasin. Antigen-presenting
phytohemagglutinin (PHA)-treated T cell blasts and the melanoma
cell-line Mel518 were transduced to express the UL49.5 proteins
of VZV and BHV-1. While the presence of BHV-1 UL49.5 greatly
reduced specific lysis of the PHA-blasts by CTLs, the expression of
VZV UL49.5 had no detectable effect (Fig. 3B). This was observed
for HLA-A1 and HLA-A2-restricted CTL clones. VZV UL49.5-
expressing and control target cells induced IFNc production by the
CTLs, while reduced IFNc production was observed when BHV-1
UL49.5 was expressed by the target cells (Fig. 3C). This reflects
effective inhibition of CTL recognition by BHV-1 but not VZV
UL49.5. Thus, despite the interaction of the VZV UL49.5 protein
with the peptide-loading complex, no interference with MHC class
I-restricted antigen presentation could be detected.
UL49.5 is responsible for the inhibition of TAP in virus-
infected cells
Having observed that the UL49.5 proteins of BHV-1, PRV,
EHV-1, and EHV-4 interfere with MHC class I-restricted antigen
presentation when expressed individually, we next investigated
whether the various UL49.5 proteins are responsible for TAP
inhibition during infection with BHV-1, PRV, or EHV-1. Peptide
transport activity was examined in natural host cells infected with
wild type viruses or with the corresponding recombinant viruses
lacking a functional UL49.5 gene [41,43]. Whereas the wild-type
viruses effectively blocked peptide transport, this inhibition was not
observed in cells infected with the mutant viruses lacking UL49.5
(Fig. 4). These findings indicate that during infection with BHV-1,
PRV and EHV-1, the UL49.5 gene products of these viruses are
responsible for the inhibition of peptide translocation by TAP
observed in virus-infected cells previously [50–52].
UL49.5 protein of BHV-1 but not of PRV or EHV-1 reduces
TAP1 and TAP2 steady state levels
Next, the mechanism of TAP inhibition by the various UL49.5
proteins was investigated. Expression of BHV-1 UL49.5 strongly
reduced TAP1 and TAP2 protein levels in human MJS cells [11].
It was shown that the cytoplasmic domain of UL49.5 is required
for mediating proteasome-dependent degradation of TAP. To
investigate whether BHV-1 UL49.5 has a similar mode of action
in natural host cells, bovine MDBK cells were infected with wild
type BHV-1 or a recombinant virus expressing a UL49.5 protein
that lacks its cytoplasmic domain (UL49.5Dtail). Steady state
protein levels of bovine TAP were evaluated by immunoblotting.
Whereas bovine TAP was readily detectable in uninfected MDBK
cells, it was no longer observed in cell lysates from wild-type BHV-1
infected cells (Fig. 5; upper panel, compare lanes 1 and 2).
Interestingly, in cells infected with the recombinant virus expressing
the UL49.5Dtail mutant, TAP1 steady state levels were not affected
(compare lanes 2 and 3). As a control, a-tubulin was consistently
detected in all samples (Fig. 5, middle panel). Immunoprecipitation
of UL49.5 from the infected cells confirmed the expression of the
wild-type and recombinant proteins (Fig. 5; lower panel). These
findings indicate that the degradation of TAP by UL49.5 previously
observed in human cells also occurs in bovine cells. In addition, like
in human cells, the cytoplasmic domain of UL49.5 is critical to TAP
degradation in the natural host cells.
To further address the molecular basis of TAP inhibition
mediated by PRV, EHV-1, EHV-4, and CHV UL49.5, these
proteins were stably expressed in human melanoma (MJS) cells.
Like BHV-1 UL49.5, the PRV and EHV-1 UL49.5 proteins were
capable of blocking human TAP (Fig. 6A). CHV UL49.5 did not
inhibit peptide transport in human cells, while in canine cells some
reduction in TAP activity was observed without a reduction of
MHC class I surface expression (Fig. 2A and B). Expression of
BHV-1 UL49.5 in MJS cells resulted in reduced TAP1 and TAP2
protein levels, which is in accordance with previous observations
(Fig. 6B; compare lanes 1 and 2) [11]. In contrast, expression of
the UL49.5 homologs of PRV and EHV-1 did not affect TAP1
and TAP2 steady state levels in MJS cells (Fig. 6B; lanes 3 and 4).
These findings indicate that the UL49.5 homologs of PRV and
EHV-1 inhibit peptide transport by TAP through a different
mechanism than by mediating degradation of TAP.
Peptide binding to TAP is not affected by EHV-1 and PRV
UL49.5 proteins
The translocation of peptides into the ER lumen is initiated by
the association of peptides with the peptide-binding site of TAP
[53]. To investigate whether the inhibition of peptide transport by
Figure 4. UL49.5 is responsible for TAP-inhibition in virus-infected natural host cells. Bovine cells (MDBK), porcine cells (PK15), and equine
cells (E.derm) were infected with wild type BHV-1, PRV, or EHV-1, respectively, or with the corresponding UL49.5-negative recombinant viruses. In all
experiments, mock-treated (uninfected) cells from the relevant host species were used as a control. Peptide transport was assessed at 5 hrs post-
infection in the presence and absence of ATP (black and open bars, respectively). The data are expressed as percentage of translocation, relative to
the translocation observed in control cells (defined as 100%).
doi:10.1371/journal.ppat.1000080.g004
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PRV and EHV-1 UL49.5 involves blocking of peptide binding to
TAP, microsomes were isolated from MJS cells expressing PRV
and EHV-1 UL49.5. Microsomes were incubated with a 125I-
labeled reporter peptide (Fig. 7). At all concentrations tested, the
peptide-binding capacity (Bmax) was similar for microsomes
prepared from control cells and from cells expressing the PRV
or EHV-1 UL49.5 proteins. Most importantly, the binding affinity
(Kd) for the peptides was not changed by the viral inhibitors,
demonstrating preservation of the peptide binding site of the TAP
complex. This has also been observed for BHV-1 UL49.5 [11] and
indicates that inhibition of TAP-mediated peptide transport by the
BHV-1, PRV, and EHV-1 UL49.5 proteins does not rely on
interference with peptide binding.
EHV-1 UL49.5 inhibits ATP-binding by TAP
Since ATP-binding and hydrolysis are required to energize
peptide translocation by TAP [54–56], it was investigated whether
the expression of the PRV, EHV-1, and EHV-4 UL49.5 proteins
affected binding of ATP to TAP. Previous experiments indicated
that the BHV-1 UL49.5 protein did not influence the interaction
of ATP with TAP [11]. The ATP-binding capacity of TAP in
lysates from MJS cells (control) was compared to the binding in
lysates from MJS cells stably expressing UL49.5 of PRV, EHV-1
or EHV-4, or the HCMV-encoded US6 protein. US6 is known to
strongly inhibit ATP-binding to TAP [22,24]. Cell lysates
prepared in the presence of the mild detergent digitonin were
incubated with ATP-agarose beads. Proteins bound to the ATP-
agarose (Fig. 8; pellet ‘‘P’’) were eluted from the beads with EDTA
and displayed next to the unbound supernatant fractions (Fig. 8;
‘‘S’’). TAP1 and TAP2 were detected by immunoblotting.
PRV UL49.5 did not alter the binding of ATP to TAP1 or
TAP2 (Fig. 8A; compare lanes 2 and 4). As expected, the
expression of US6 completely abolished the interaction of ATP
with TAP (Fig. 8A; lane 6). These data show that TAP retains the
capacity to bind ATP in the presence of PRV UL49.5.
In EHV-1 and EHV-4 UL49.5-expressing cells, neither TAP1
nor TAP2 could be detected in the ATP-agarose fraction (Fig. 8B;
compare lane 2 with lanes 4 and 8). Since the C-terminus of
UL49.5 is exposed in the cytosol, this domain might be responsible
for the inhibition of ATP-binding to the nucleotide-binding
domains of TAP. To evaluate whether the C-terminus of
UL49.5 blocks ATP-binding to TAP, a truncated form of EHV-
1 UL49.5 lacking the cytoplasmic domain was constructed and
expressed in MJS cells. The EHV-1 UL49.5Dtail recombinant still
interfered with ATP-binding to TAP (Fig. 8B; lane 6). When the
association of wild type or mutant EHV-1 UL49.5 with TAP was
disrupted by lysis of the cells in NP-40, the ability of TAP1 and
TAP2 to bind to the ATP-agarose was restored (Fig. 8C, lanes 4
and 6; also compare Fig. 8B lanes 4 and 6 with Fig. 8C lanes 4 and
6, respectively). These results indicate that the EHV-1 UL49.5
Figure 6. UL49.5 of BHV-1 but not of PRV or EHV-1 reduces
TAP1 and TAP2 steady state levels in human cells. (A) TAP-
dependent peptide transport is inhibited in human melanoma cells
(MJS) stably expressing the UL49.5 homologs of BHV-1, PRV and EHV-1,
but not CHV. Peptide transport is depicted as percentage of
translocation, relative to the translocation observed in control cells
(defined as 100%). (B) Steady state protein levels of TAP1, TAP2, MHC
class I heavy chains (MHC I HC), and UL49.5 in control cells and cell lines
expressing UL49.5 of BHV-1, PRV and EHV-1. Proteins present in post-
nuclear supernatants were separated using SDS-PAGE and detected by
immunoblotting (IB) using antibodies specific for TAP1, TAP2, MHC class
I heavy chains, and the UL49.5 proteins of BHV-1, PRV and EHV-1. *The
doublet of PRV UL49.5 is probably related to differential glycosylation.
doi:10.1371/journal.ppat.1000080.g006
Figure 5. Degradation of bovine TAP is mediated by BHV-
1UL49.5 through its cytoplasmic tail.MDBK cells were mock-infected
or infected with wild type BHV-1 or BHV-1 expressing UL49.5Dtail for
12 hours. The levels of bovine TAP1 and, as a control, a-tubulin were
assessed in lysates of infected cells by immunoblotting (IB). BHV-1 UL49.5
was immunoprecipitated from lysates of metabolically labeled cells (IP).
doi:10.1371/journal.ppat.1000080.g005
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protein is capable of interfering with the recruitment of ATP by
human TAP independent of the cytoplasmic domain of UL49.5.
The ability of EHV-1 and EHV-4 UL49.5 to interfere with the
binding of ATP to equine TAP was assessed in E. derm cells (data
shown for EHV-4). Like human TAP (Fig. 8B lane 8), equine
TAP2 was not able to bind ATP-agarose in the presence of EHV-4
UL49.5 (Fig. 8D; compare lanes 2 and 4). When the experiment
was performed in the presence of NP-40, the ability of equine
TAP2 to bind ATP was restored (Fig. 8D; compare lanes 4 and 6).
These results indicate that the UL49.5 proteins of EHV-1 and
EHV-4 inhibit human and equine TAP through similar
mechanisms, rendering both human and equine TAP molecules
incapable of recruiting ATP.
UL49.5 proteins arrest TAP in a translocation-
incompetent state
To obtain further insight into the strategies used by EHV-1 and
PRV UL49.5 to block TAP transport, Fluorescence Recovery
After Photobleaching (FRAP) assays were performed. With this
technique, conformational changes of TAP that occur during
peptide translocation can be indirectly visualized by measuring the
lateral mobility of green fluorescence protein (GFP)-tagged TAP
within the ER membrane. It has been shown that the lateral
mobility of TAP is inversely proportional to its activity, as peptide-
transporting TAP molecules diffuse at a slower rate than inactive,
closed TAP complexes [57]. In the absence of ATP, the
translocation cycle cannot be initiated and consequently TAP will
have a closed, more compact conformation. In agreement with
this, depletion of ATP results in increased mobility of TAP in the
ER membrane (Fig. 9; control samples, compare black and grey
bars). The complex can be trapped in the active conformation by
adding long side chain peptides (l.s.c.p.). These peptides bind to
TAP, but cannot be translocated over the ER membrane, which
results in a retained open conformation and therefore a slow
diffusion rate of TAP in the ER membrane [57] (Fig. 9; control
samples, white bar).
Expression of EHV-1 and PRV UL49.5 results in a decreased
mobility of TAP (Fig. 9; compare untreated samples/black bars).
Whereas the diffusion rate of TAP increased considerably in ATP-
depleted control cells, only a slight increase in TAP mobility was
detected upon ATP depletion in the UL49.5-expressing cells (grey
bars). The failure of TAP to respond to ATP depletion in the
EHV-1 UL49.5 cells is in agreement with the observation that this
protein interferes with ATP binding to TAP (Fig. 8B). Although
ATP can still bind to TAP in the presence of PRV UL49.5
(Fig. 8A), ATP depletion induces only a minor change in TAP
mobility in the PRV UL49.5 cells (Fig. 9). Apparently, the
Figure 8. UL49.5 of EHV-1 and EHV-4 block ATP binding to
human and equine TAP. (A, B, C) MJS cells expressing the UL49.5
proteins or the HCMV-derived TAP-inhibitor US6 and (D) E.derm cells
expressing EHV-4 UL49.5 were lysed using digitonin or NP40 as
indicated. Post nuclear lysates were incubated with ATP-agarose. The
pellet (P) contains the ATP-binding proteins. The supernatant (S)
contains proteins incapable of binding ATP. ATP-bound (ATP-agarose
beads; pellet) and unbound (soluble; supernatant) fractions were
separated by centrifugation and analyzed using SDS-PAGE and
immunoblotting (IB) with antibodies against the proteins indicated.
doi:10.1371/journal.ppat.1000080.g008
Figure 7. UL49.5 of PRV and EHV-1 do not interfere with peptide
binding to TAP. To evaluate peptide binding to the TAP complex,
microsomal membranes from MJS TAP1-GFP cells (control; &), or MJS
TAP1-GFP cells expressing UL49.5 of PRV (m) or EHV-1 (.) were incubated
with increasing concentrations of the radiolabeled peptide (RR[125I]YQK-
STEL). Unspecific binding was determined in the presence of 200-fold
excess of ICP47 (data not shown). The amount of specifically bound
peptide per amount of microsomal protein is plotted against the peptide
concentration. Kd values for control MJS: 277658 nM, for MJS UL49.5
PRV:
351642 nM and for MJS UL49.5EHV-1: 236671 nM.
doi:10.1371/journal.ppat.1000080.g007
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presence of PRV UL49.5 prohibits conformational transitions that
normally follow ATP-binding.
In the presence of the UL49.5 proteins, l.s.c.p. were also unable
to induce conformational changes within the TAP complex (Fig. 9).
Since peptides can still bind to TAP in the presence of EHV-1 and
PRV UL49.5 (Fig. 7), the failure of l.s.c.p. to induce conforma-
tional changes again suggests that the UL49.5 proteins arrest TAP
in a translocation-incompetent state.
Discussion
This study identifies the UL49.5 proteins of BHV-1, PRV,
EHV-1, and EHV-4 as members of a novel class of viral immune
evasion proteins. The UL49.5 gene products interfere with MHC
class I antigen presentation by blocking the supply of antigenic
peptides in the ER lumen through inhibition of TAP. Within the
UL49.5 family of TAP inhibitors, heterogeneity is observed with
respect to the mechanisms that underlie TAP inhibition. Whereas
BHV-1 UL49.5 targets TAP for proteasomal degradation [11],
PRV and EHV-1 UL49.5 do not diminish the steady state levels of
TAP1 or TAP2. Interestingly, EHV-1 and EHV-4 UL49.5
interfere with the binding of ATP to TAP, a function that is not
influenced by BHV-1 or PRV UL49.5. All TAP-inhibiting UL49.5
proteins arrest the transporter complex in a translocation-
incompetent state.
UL49.5 homologs are encoded by all Herpesviridae analyzed to
date [38]. However, the TAP-inhibiting capacities of these
proteins appear to be restricted to certain members of the genus
Varicellovirus. Members of this virus genus have co-evolved with
their respective host species [39]. Viruses of even-toed ungulates or
Artiodactyla like BHV-1 and PRV co-evolved with cattle and pigs;
viruses of odd-toed ungulates or Perissodactyla (EHV-1 and EHV-4)
with horses; the carnivore viruses FHV-1 and CHV with cats and
dogs, and the Old World primate virus VZV with humans [39]
(Fig. 10). The identification of the UL49.5 proteins encoded by
BHV-1, PRV, EHV-1, and EHV-4 as members of the UL49.5
family of TAP inhibitors suggests that more UL49.5 proteins with
this property may be found in varicelloviruses of even- and odd-
toed ungulate hosts. Considering the shared evolution of
(herpesviruses from) carnivores and (herpesviruses from) odd-toed
ungulates [39], CHV UL49.5 was expected to inhibit TAP as
effectively as EHV-1 and EHV-4 UL49.5. However, the reduction
of TAP-dependent peptide transport caused by CHV UL49.5 was
very moderate compared to the inhibition by the other TAP-
inhibiting UL49.5 proteins. The identification of the UL49.5
domains contributing to TAP inhibition will provide more insights
into these differences.
VZV infection of human cells results in reduced expression of
MHC class I at the cells surface [45–47]. The VZV ORF66-
encoded serine-threonine protein kinase has been shown to be one
of the VZV proteins contributing to MHC class I down-regulation
in VZV-infected cells [47]. However, a VZV recombinant lacking
a functional ORF66 product still causes down-regulation of MHC
class I surface expression, indicating that additional modulators of
MHC class I-restricted antigen presentation are encoded by VZV.
The observed down-regulation of MHC class I surface expression
on VZV-infected cells [45–47] is not induced by UL49.5 when
expressed individually. Despite the observed interaction between
VZV UL49.5 and the peptide-loading complex, this protein alone
did not block peptide transport by TAP and it had no effect on
antigen recognition by HLA-A1 and HLA-A2-restricted CTL
clones. As VZV occupies a somewhat isolated position in the
phylogenetic tree of varicelloviruses (Fig. 10), it seems likely that
evolutionary divergence has influenced VZV to acquire a separate
mechanism to interfere with MHC class I-restricted antigen
presentation. Alternatively, UL49.5 might co-operate with another
unidentified VZV-encoded protein in order to reduce antigen
presentation by MHC class I molecules. During virus infection,
UL49.5 can be found in a complex with glycoprotein M (gM).
However, the co-expression of VZV UL49.5 and glycoprotein M
has no effect on the expression of MHC class I molecules at the
cell surface [47], indicating that gM does not act as a modulator of
UL49.5 with respect to TAP inhibition.
Interaction with the conserved viral membrane glycoprotein M
appears to be a common property of all UL49.5 homologs, as is
the presence of a single cysteine residue in their ER-luminal/
extracellular domain [41–44]. This cysteine residue is involved in
the interaction of UL49.5 with gM, with which it forms a disulfide-
linked heterodimers [37,40]. The complex of UL49.5 and gM is
implicated in virion maturation and membrane fusion processes
[58,59]. Interestingly, the interaction of BHV-1 UL49.5 with gM
interferes with its capacity to block TAP [42]. Nevertheless,
UL49.5 blocks peptide transport by TAP in BHV-1-infected cells.
This may be explained by the fact that UL49.5 is expressed prior
to and in excess of the early-late gM [42].
Interference with TAP-mediated peptide transport is an
effective way of reducing CTL recognition and is used by several
other herpesviruses, including HSV-1 and -2, HCMV, MHV-68,
and EBV [12–36]. Compared to the other herpesvirus-encoded
TAP inhibitors, the cross-species activity of UL49.5 proteins is
remarkable. Except for CHV UL49.5, the UL49.5 proteins of
BHV-1, PRV, EHV-1, and EHV-4 all exhibit the ability to target
human TAP. In addition, BHV-1 UL49.5 inhibits peptide
transport by murine [60], rat, equine, and porcine TAP (D.K.L.
and M.V., unpublished observations). Human, porcine, bovine,
and rodent TAP1 and TAP2 demonstrate a substantial degree of
amino acid identity (70–80%) [61]. Thus, the ability of UL49.5
proteins to act across species barriers most likely relies on
structural homology within the TAP domains critically involved
in UL49.5-TAP interaction. Apparently, this is less so for the
domains within TAP that are targeted by US6, mK3 and
BNLF2a, whose actions seem to be restricted largely to the
Figure 9. UL49.5 homologs arrest TAP in a translocation-
incompetent state. The lateral mobility of the TAP complex was
analyzed in MJS TAP1-GFP cells using confocal microscopy and FRAP. A
circular spot in the ER was bleached and recovery of fluorescence was
monitored. The half-time for recovery was determined and used to
calculate the diffusion coefficient D. Where indicated, ATP was depleted
(-ATP) or saturating amounts of substrate peptides (long side chain
peptides, l.s.c.p.) were micro-injected into the cells.
doi:10.1371/journal.ppat.1000080.g009
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natural host species. BHV-1 UL49.5 reduces TAP protein levels in
bovine, human, and murine cells, and also mediates degradation
of human TAP in insect cells when co-expressed with UL49.5
[11,60,62], indicating conservation of the pathway involved in this
degradation process.
The UL49.5 proteins exhibit unexpected differences in their
mechanisms of TAP inhibition, despite their close evolutionary
relatedness. The cytoplasmic domain of BHV-1 UL49.5 is
essential for mediating degradation of both human and bovine
TAP. EHV-1 and PRV UL49.5 have no influence on the stability
of TAP. Apparently, degradation of TAP is facilitated by a yet
unknown signal within the C-terminal domain of BHV-1 UL49.5,
which is not present in the other homologs. Studies to identify the
nature of this sequence motif are in progress.
The interaction of EHV-1 and EHV-4 UL49.5 with TAP blocks
ATP binding to TAP. This feature distinguishes EHV UL49.5
from the other homologs studied. Interestingly, removal of the
cytoplasmic domain of the EHV-1 UL49.5 protein did not restore
the ability of TAP to bind ATP. Therefore, a direct interaction of
EHV-1 UL49.5 with the cytosolic nucleotide binding domains of
TAP is unlikely. Instead, the viral protein appears to arrest TAP in
a translocation-incompetent state, incompatible with ATP-bind-
ing. This may resemble the type of structural change caused by
HCMV US6 [23,63]. US6, a type I transmembrane protein,
interacts with the luminal side of the TAP transporter and blocks
ATP-binding by prohibiting essential conformational rearrange-
ments within TAP. The inability of the BHV-1 and PRV UL49.5
homologs to interfere with ATP-binding could be due to a slightly
different conformational change induced by these proteins.
Based on the results presented in this study, the UL49.5 proteins
encoded by BHV-1, PRV, EHV-1, and EHV-4 can be classified as
a new family of TAP-inhibiting proteins. These proteins share the
ability of inducing a conformational arrest of TAP, which results in
impaired peptide transport and inhibition of MHC class I-
Figure 10. Phylogenetic tree of alphaherpesvirus UL49.5 proteins constructed on the basis of all presently known UL49.5 amino
acid sequences of Alphaherpesvirinae using ClustalV. The ClustalV (PAM250) method was used under the default settings of the alignment
program MegAlignTM 500 of the sequence analysis software DNA* of DNASTAR Inc. The UL49.5 proteins for which TAP inhibition has been tested are
shown in bold. *The HHV-3 (VZV) UL49.5 protein binds TAP, but does not block peptide transport. The NCBI accession numbers are provided in
Materials and Methods.
doi:10.1371/journal.ppat.1000080.g010
TAP Inhibition by Varicellovirus UL49.5
PLoS Pathogens | www.plospathogens.org 9 May 2008 | Volume 4 | Issue 5 | e1000080
restricted antigen presentation. In view of these joint features it is
likely that the TAP inhibiting UL49.5 proteins originate from a
common ancestral protein, which acquired this capacity earlier
during evolution. The VZV UL49.5 protein may be a rudimen-
tary form with respect to TAP inhibition, or it may have lost its
TAP inhibitory capacity later on. Alternatively, it may require
additional VZV proteins for the inhibition of TAP.
This study has revealed unexpected variation among UL49.5
proteins of varicelloviruses with respect to their mechanisms of TAP
inhibition. These differences can be related to distinct evolutionary
pathways of these varicelloviruses. The UL49.5 family of TAP-
inhibiting proteins does not demonstrate any structural or functional
similarity to TAP-inhibiting proteins encoded by other herpesvirus-
es, for instance ICP47, US6, mK3, or BNLF2a. This diversity of
TAP-inhibiting proteins acquired by distantly related members of
the subgroups of alpha-, beta-, and gammaherpesviruses is
remarkable and presents a striking example of functional convergent
evolution. At the same time, this identifies TAP as an Achilles’ heel of
the MHC class I antigen presentation pathway. Inhibition of TAP
has apparently provided a strong advantage to these herpesviruses
during co-evolution with their hosts.
Materials and Methods
UL49.5 constructs
Purified viral DNA from BHV-1 strain Lam and CHV strain
Eva (Animal Sciences Group, Lelystad, The Netherlands), PRV
strain Kaplan [41], EHV-1 strain Ab-4 (kindly provided by J.
Rola; National Veterinary Research Institute, Pulawy, Poland)
and EHV-4 (kindly provided by R. de Groot; Dept. of Infectious
Diseases and Immunology, Utrecht University, The Netherlands),
and VZV (viral DNA extracted from patient material; kindly
provided by E. Klaas, Leiden University Medical Center, Leiden,
The Netherlands) were used as a template for polymerase chain
reaction (PCR) amplification. PCR-reactions were performed
under standard conditions using Pfu DNA polymerase (Invitrogen)
and specific primers (Table 1) for amplification of the full length
coding sequence of the UL49.5 genes of BHV-1 [11], PRV, EHV-
1, EHV-4, CHV and VZV UL49.5. The sequences of the primers
are based on published sequences found in the NCBI database,
except for the sequence of the CHV primers (Haanes, E. and
Rexann, F. ‘Recombinant canine herpesviruses’, patent number
EPO910406, publication date 1997-08-21). To generate the EHV-
1 UL49.5Dtail construct, primers (Table 1) were used to obtain a
PCR product lacking 39-terminal 45 nucleotides, thereby deleting
the 15 carboxy-terminal amino acids. PCR-generated products
were sequenced and inserted into the retroviral expression vectors
pLZRS-IRES-GFP or pLZRS-IRES-DNGFR, upstream of the
internal ribosome entry site (IRES) element. pLZRS vector
information can be obtained at www.stanford.edu/group/nolan/
retroviral_systems/ retsys.html).
Cell Lines and Retroviral Transduction
The human melanoma cell line Mel JuSo (MJS), MJS TAP1-
GFP [57] and Madin-Darby bovine kidney (MDBK) cells
(American Type Culture Collection, ATCC) were maintained in
RPMI-1640 medium; GP2-293 cells, porcine kidney (PK15) cells,
the embryonic bovine trachea (EBTr) cell line, Madin-Darby
canine kidney I (MDCK I) cells, and the equine epithelial cell line
E.derm were maintained in DMEM medium. Media were
supplemented with 10% heat-inactivated fetal bovine serum
(FBS) (with the exception of E.derm cells that required 20%),
2 mM L-glutamine (Invitrogen), 140 IU/ml penicillin and
140 mg/ml streptomycin. PHA-treated T-cell blasts positive for
HLA-A1 and HLA-A2 were generated from PBMCs by
stimulation with 0.8 mg/ml PHA and were subsequently cultured
in IMDM supplemented with 100 IU/ml IL-2 and 10% FBS. The
HLA-A2-expressing melanoma cell line 518, Mel518 (a kind gift
from E. Verdegaal, department of Clinical Oncology, Leiden
University Medical Center, Leiden, The Netherlands) was
maintained in DMEM containing 4.5 mM glucose, supplemented
with 8% FBS, 2 mM L-glutamine (Invitrogen), 140 IU/ml
penicillin and 140 mg/ml streptomycin.
Recombinant retroviruses were prepared using the Phoenix
amphotropic packaging system as described previously (www.
stanford.edu/group/nolan/retroviral _systems/retsys.html). MJS,
MDCK I, PK15, and E.derm cells were transduced with
recombinant retroviruses to generate the following stable cell
lines: MJS, MDCK I, PK15, and E.derm controls (containing
BHV-1 UL49.5 in the anti-sense orientation, GFP+); MJS
UL49.5BHV-1, PHA T-cell blast UL49.5BHV-1 and Mel518
UL49.5BHV-1 (containing BHV-1 UL49.5 in the sense orientation
(SO), GFP+); MJS UL49.5VZV, PHA T-cell blast UL49.5VZV and
Mel518 UL49.5VZV (containing VZV UL49.5 SO, GFP+); MJS
UL49.5CHV and MDCK I UL49.5CHV (containing CHV UL49.5
SO, GFP+); MJS UL49.5PRV and PK15 UL49.5PRV (containing
PRV UL49.5 SO, GFP+); MJS UL49.5EHV-1 and E.derm
UL49.5EHV-1 (containing EHV-1 UL49.5 SO, GFP+); MJS
UL49.5EHV-1Dtail (containing tail-less EHV-1 UL49.5 SO,
GFP+); MJS UL49.5EHV-4 and E.derm UL49.5EHV-4 (containing
EHV-4 UL49.5 SO, GFP+). In addition, MJS TAP1-GFP cells
were transduced with recombinant retrovirus to generate MJS
TAP1-GFP control (containing the empty pLZRS construct,
DNGFR+); MJS TAP1-GFP UL49.5BHV-1 (containing BHV-1
UL49.5 SO, DNGFR+); MJS TAP1-GFP UL49.5PRV (containing
PRV UL49.5 SO, DNGFR+) and MJS TAP1-GFP UL49.5EHV-1
(containing EHV-1 UL49.5 SO, DNGFR+). To generate recom-
binant retroviruses for MDBK cell line transductions, the GP2-293
pantropic packaging cell line was used according to the protocol
obtained from BD Bioscience Clontech (www.bdbiosciences.com).
In brief, 16106 of GP2-293 cells were co-transfected with
retroviral expression vector (pZLRS-IRES-GFP containing the
BHV-1 UL49.5 gene in anti-sense or in the sense orientation) and
pVSV-G construct (envelope vector) for retrovirus production.
Retrovirus-containing medium was collected 48 hours post-
transfection. MDBK cells were transduced four times with VSV-
Table 1. PCR primers used
Primer name
Primer sequence (restriction enzymes used in
bold)
PRV UL49.5 Fw: 59-CGCGGATCCGACACACCAGGATGGTC-39
PRV UL49.5 Rev: 59-GCGGAATTCGGATCGCTCTTTATACGC-39
EHV-1UL49.5 Fw: 59-GCCGCCACCATGCTGTCCACGAGATTC-39
EHV-1UL49.5 Rev: 59-TTGTCAATGCAGGTGTTGCAACATCTC-39
EHV-1UL49.5Dtail Fw: 59-GAGAATTCAGGACCATGCTGTCCACGAGATTC-39
EHV-1UL49.5Dtail Rev: 59-CGCTCGAGCTTCAGCGGTATGCCTG-39
EHV-4 UL49.5 Fw: 59-GCCGCCACCATGTTGTCAGCGAGATTAG-39
EHV-4 UL49.5 Rev: 59-TGCTCAGTGTAGGTGTCGCAAATC-39
CHV UL49.5 Fw: 59 -GCCGCCACCATGGAGATAGTATTTTTAC-39
CHV UL49.5 Rev: 59 -CCATTAGTGTTGCATCTGACGAAGTTC-39
VZV UL49.5 Fw: 59-GCCGGATCCAAGATGGGATCAATTAC-39
VZV UL49.5 Rev: 59-CCGGAATTCCGGTTACCACGTGCTGCG-39
doi:10.1371/journal.ppat.1000080.t001
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G containing recombinant retroviruses to generate the following
stable cell lines: MDBK control (containing BHV-1 UL49.5 in
anti-sense orientation, GFP+) and MDBK UL49.5BHV-1 (contain-
ing BHV-1 UL49.5 SO, GFP+). All cell lines generated in this
study were selected for GFP or DNGFR expression using a
FACSVantage cell sorter (Becton Dickinson). To obtain MJS cells
stably expressing the HCMV-encoded US6 (MJS US6), MJS cells
were transfected with pcDNA3-US6-IRES-NLS-GFP and selected
for neomycin resistance [64].
Reagents
The following antibodies were used in this study: anti-transferrin
receptor (TfR) monoclonal antibody (mAb) 66Ig10, anti-TfR mAb
H68.4 (Roche), anti-human MHC class I complexes mAb W6/32,
anti-human MHC class I heavy chain mAb HC-10 (kindly provided
by H. Ploegh, Whitehead Institute, Cambridge, Massachusetts,
USA), anti-human class II HLA-DR mAb Tu¨36 (kindly provided by
A. Ziegler, Institute for Immunogenetics, Universita¨tsklinikum
Charite´, Berlin, Germany), anti-TAP1 mAb 148.3 [54] and anti-
TAP2 mAb 435.3 (kind gift from P. van Endert, Institut National de
la Sante´ et de la Recherche Me´dicale, Paris, France). For the
detection of equine TAP2, the polyclonal antibody anti-rat TAP2
Mac394 was used (kindly provided by M. Knittler, Institute of
Immunology, Friedrich-Loeffler-Institute, Tu¨bingen, Germany). For
preparation of bovine TAP1 specific antibody, the bovine TAP1
ORF sequence encoding amino acid residues 117 to 167 were
amplified from bovine genomic DNA and cloned into pGEX-4T-2
(GE Healthcare). The TAP1 polypeptide encompassing residues
aa117-167 was purified as described previously [65]. The monoclo-
nal antibody IL-A19 directed against bovine MHC class I molecules
(a kind gift fromDr. J. Naessens, ILRAD, Nairobi, Kenya). The anti-
equine and anti-canine MHC class I complexes mAb H58A and
anti-porcine MHC class I mAb PT85A were purchased from
VMRD Inc., Pullman, WA, U.S.A.
Mouse anti-BHV-1 UL49.5 serum was kindly provided by G.J.
Letchworth (University of Wisconsin, Madison, Wisconsin, USA).
Polyclonal rabbit anti-BHV-1 UL49.5 serum H11 was raised
against a synthetic peptide representing the N-terminal sequence
of BHV-1 UL49.5 and has been described [42]. In fig. 5, a
different polyclonal rabbit anti-BHV-1 UL49.5 was used, obtained
using a synthetic peptide corresponding to amino acid residues 27–
41 of UL49.5 ([H] DAMRREGAMDFWSAGC*-[OH]). To
facilitate conjugation to keyhole limpet hemocyanin, an additional
irrelevant cysteine was added at the C terminus of the peptide
(indicated by *). Rabbits were immunized by as described earlier
[66]. The rabbit antiserum raised against PRV UL49.5 (gN) has
been described [67], as was the anti-EHV-1 UL49.5 rabbit serum
[43]. The VZV UL49.5-specific antibody was raised against two
synthetic peptides: the N-terminal peptide EPNFAERNF-
WHASCSARGVYIDGSMITTLFKK and the C-terminal pep-
tide RLFTRSVLRSTW. Both peptides were conjugated to
glutathione S-transferase (GST) according to the methods
described in [42]. The peptide-GST conjugates were mixed at a
1:1 ratio and emulsified in Freund’s complete adjuvant for the first
immunization and Freund’s incomplete for the following immu-
nizations. At 3-weeks intervals, the rabbit received four additional
subcutaneous immunizations with the conjugates.
Flow Cytometry
Cells were trypsinized and resuspended in phosphate-buffered
saline (PBS) containing 1% bovine serum albumin (BSA) and
0.05% sodium azide. Cells were incubated with specific antibodies
on ice for one hour. After washing, the cells were incubated with
phycoerytrin (PE)-conjugated anti-mouse antibody for 45 min.
Stained cells were analyzed by flow cytometry on a FACSCalibur
flow cytometer (Becton Dickinson). To exclude dead cells, 7-
aminoactinomycin D (7-AAD, Sigma-Aldrich) was added at a
concentration of 0.5 mg/ml to all samples before analysis. Cells
were analyzed using CellQuest software (Becton Dickinson).
Peptide Transport Assay
The fluorescence-based peptide transport assay was performed
as previously described [11,68]. In brief, MJS cells were
permeabilized with Streptolysin O (Murex Diagnostics Ltd.) at
37uC, followed by incubation with the fluorescein-conjugated
synthetic peptide CVNKTERAY (N-core glycosylation site under-
lined) in the presence or absence of ATP. Peptide translocation was
terminated by adding ice-cold lysis buffer containing 1% Triton X-
100. After lysis, cell debris was removed by centrifugation, and
supernatants were collected and incubated with Concanavalin A
(ConA)-Sepharose (Amersham). After extensive washing of the
beads, the peptides were eluted with elution buffer (500 mM
mannopyranoside, 10 mM EDTA, 50 mM Tris-HCl pH 8.0) by
vigorous shaking and further separated from ConA by centrifugation
at 12,0006g for 2 minutes. The fluorescence intensity was measured
using a fluorescence plate reader (CytoFluor, PerSeptive Biosystems;
excitation 485 nm/emission 530 nm). The data were analyzed using
the unpaired t-test. Statistical significance was set at p ,0.05.
Immunoprecipitations, Immunoblotting and
Radiolabeling
Cells were lysed in a buffer containing 1% (wt/vol) digitonin,
50 mM Tris?HCl (pH 7.5), 5 mM MgCl2, 150 mM NaCl, 1mM
leupeptin, and 1 mM AEBSF (4-(2-Aminoethyl)-benzenesulfonyl
fluoride), and subjected to immune precipitations using anti-TAP1
mAb 148.3 o/n. To determine steady state protein levels, cells were
lysed in Nonidet P-40 (NP-40) lysis mix containing 50 mM Tris-
HCl, pH 7.4, 5 mM MgCl2 and 0.5% NP-40, supplemented with
1 mM AEBSF (4-(2-Aminoethyl)-benzenesulfonyl fluoride), 1 mM
leupeptin and 20 mM Cbz-L3 (Carbobenzoxy-1-Leucyl-1-Leucyl-1-
Leucinal-H; Peptides International, Inc). The samples were kept on
ice throughout the experiment. Protein complexes were denatured in
reducing sample buffer (2% SDS, 50 mM Tris pH 8.0, 10%
glycerol, 5% b-ME, 0.05% bromophenol blue) for 5 min at 96uC.
Immunoblotting (IB) analysis was performed on denatured cell
lysates separated by SDS-PAGE and blotted onto polyvinylidene
fluoride (PVDF) membranes. Blots were incubated with the
antibodies as indicated, followed by horseradish peroxidase-
conjugated goat-anti-mouse or swine-anti-rabbit Igs (DAKO and
Jackson Laboratories), and visualized by ECLplus (Amersham).
Steady-state labeling of MDBK cells with [35S]-methionine/
cysteine and subsequent immunoprecipitations with rabbit BHV-1
UL49.5-specific antibody were performed as described [69].
Immunoblotting procedures with rabbit anti-bovine TAP1 and
rabbit anti-a-tubulin have been described [65].
Cytotoxicity Assay
A total of 1,000 51Cr-labeled target cells were incubated with
different CD8+ CTL clones at various effector to target ratios. The
HY-A1 clone recognizes an HY epitope in the context of HLA-A1,
and the HA2.27 clone recognizes the histocompatibility antigen
HA-2 in the context of HLA-A2. After 4 hours of incubation at
37uC, 51Cr release into the supernatant was measured using
standard methods. The mean percentage of triplicate wells was
calculated as follows: % specific lysis = (experimental release–
spontaneous release)/(maximal release–spontaneous release)6100.
For analysis of IFN-c production, 20,000 T-cells were co-cultured
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with 10,000 target cells. After 24 hours, the supernatant was
harvested and the concentration of IFN-c was measured by
standard ELISA (Sanquin, Amsterdam, The Netherlands).
Viruses and Virus Infections
The wild type viruses used in this study were: BHV-1 strain
Lam, BHV-1 strain Cooper (Fig. 5), PRV strain Kaplan and
EHV-1 strain RacL1.The UL49.5 deletion mutant of PRV used in
this study has been described before [41,43]. The UL49.5 deletion
mutant of EHV-1 (strain RacL11) was a gift from J. von Einem
(College of Veterinary Medicine, Cornell University, Ithaca, NY,
USA). Infections with wild type and mutant herpesviruses were
carried out on the following cell lines: MDBK cells for BHV-1;
PK15 cells for PRV and E.derm cells for EHV-1. The cells were
washed once with PBS and infected with BHV-1 or PRV at an
m.o.i. of 10, and with EHV-1 at an m.o.i. of 5 at 37uC in serum-
free medium. After 2 hours, medium containing 10% FBS was
added. Mock-infected cells were treated under the same conditions
as infected cells. After 5 hours of infection, cells were collected and
prepared for the peptide translocation assay. For immunoblotting
and metabolic labeling experiments, MDBK cells were infected
with BHV-1 wt and UL49.5Dtail viruses for 12 hours.
Construction of BHV-1 UL49.5 recombinant viruses
The BHV-1 UL49.5 mutant was generated by homologous
recombination, using BHV-1 strain Lam as parent strain. The
recombination region upstream of the UL49.5 gene was a 1.4 kb
fragment running from nucleotide residue 7670 to 9061 (residue
numbers based on the complete BHV-1 genome with NCBI
accession number NC_001847, updated 30 March 2006). This
fragment starts at a BstXI site 1.3 kb upstream of the start codon of
the UL49.5 open reading frame and ends at its amino acid residue
31. The recombination region downstream of the UL49.5 gene was
provided by a 1.9 kb fragment from nucleotide residue 9075 to
10972. This fragment starts at amino acid residue 36 of UL49.5 and
ends at an FspI site 1.7 kb downstream of the UL49.5 open reading
frame. A 2.2 kb NruI–PvuII fragment was cloned between the two
UL49.5 recombination fragments that carries the hGFP gene in the
expression cassette of pcDNA3 (Invitrogen). The complete recom-
bination fragment (5.5 kb) was co-transfected with purified BHV-1
Lam DNA into EBTr cells using a calcium phosphate-based
transfection method. After plating the supernatant of freeze/thawed
transfected cells, a green plaque was found that, following three
rounds of plaque purification, failed to react with anti-BHV-1
UL49.5 serum. The BHV-1-UL49.5 mutant could be grown to a
titer of 107.0 TCID50/ml and was capable of penetrating bovine cells
with the same kinetics as the wild type Lam strain.
The BHV-1 recombinant virus gN Am80, expressing a form of
UL49.5 lacking its cytoplasmic domain, was constructed by
introducing an amber mutation at gN residue 80R (AGG to
TAG) by using a BHV-1 BAC clone (Liu and Chowdhury,
manuscript in preparation).
Peptide Binding Assay
Cellular microsomes were prepared as described [70]. Micro-
somes isolated from 76106 homogenized cells were pre-incubated
in 50 ml of AP buffer (5 mM MgCl2 in phosphate-buffered saline,
pH 7.0) on ice for 45 min in the absence or presence of a 200-fold
molar excess of the non-labeled TAP-specific viral inhibitor ICP47
[18]. Different concentrations of radiolabeled peptide
(RR[125I]YQKSTEL) were added equally to the samples with or
without ICP47 and incubated on ice [71]. Non-bound peptides
were removed by washing the membranes with 400 ml of AP
buffer and subsequent centrifugation at 20,000 g for 8 min. The
amount of radioactivity bound to the membranes was quantified
by c-counting and corrected for the signal obtained in the
presence of ICP47. All experiments were performed in triplicate.
ATP-Agarose Binding Assay
TAP binding to ATP-agarose was assayed as described [11]. In
brief, cells were solubilized in 1% (w/v) digitonin, 50 mM Tris-HCl
(pH 7.5), 5 mMMgCl2, 150 mMNaCl, 5 mM iodoacatamide, and
1 mM AEBSF. Hydrated C-8 ATP-agarose (Fluka/Sigma) was
added to the post-nuclear supernatant and incubated by rotation at
4uC. After 2 hours, the supernatant was separated from the ATP-
agarose pellet by 5 minutes centrifugation. The resulting pellet was
washed three times with 0.1% (w/v) digitonin, 50 mM Tris-HCl
(pH 7.5), 5 mM MgCl2 and 150 mM NaCl. Proteins bound to the
ATP-agarose were eluted with 500 mM EDTA and SDS sample
buffer was added to both the supernatant and the pellet. The samples
were separated using SDS-PAGE and analyzed by immunoblotting.
FRAP
Confocal microscopy and Fluorescence Recovery After Photo-
bleaching (FRAP) assays were performed as described [11,57]. In
short, a circular spot in the ER was bleached at full intensity, and
an attenuated laser beam was used to monitor recovery of
fluorescence. The half-time for recovery was calculated from each
recovery curve after correction for loss of fluorescence caused by
imaging (usually ,4%). The diffusion coefficient D was deter-
mined from at least seven cells measured in different experiments.
Accession numbers
UL49.5 sequence data used to generate the alignment shown in
Fig. 1 and the phylogenetic tree shown in Fig. 7, have been obtained
from the NCBI (www.ncbi.nlm.nih.gov) database with the accession
numbers: bovine herpesvirus 1 (BoHV-1) [NP_045309], bovine
herpesvirus 5 (BoHV-5) [NP_954898], cercopithecine herpesvirus 1
(CeHV-1) [AAP41468], cercopithecine herpesvirus 9 (CeHV-9)
[NP_077423], cercopithecine herpesvirus 16 (CeHV-16)
[YP_443897], equid herpesvirus 1 (EHV-1) [AAT67267], equid
herpesvirus 4 (EHV-4) [CAA35670], gallid herpesvirus 1 (GaHV-1)
[YP_182341], gallid herpesvirus 2 (GaHV-2) [NP_057812], gallid
herpesvirus 3 (GaHV-3) [NP_066882], human herpesvirus 1 (HSV-
1) [NP_044652], human herpesvirus 2 (HSV-2) [NP_044520],
human herpesvirus 3 (VZV) [YP_068406], meleagrid herpesvirus 1
(MeHV-1) [AAG30090], psittacid herpesvirus 1 (PsHV-1)
[AAQ73691], suid herpesvirus 1 (PRV) [YP_068325], transporter
1 ATP-binding cassette sub-family B [Bos taurus] [AAY34698]. Not
obtained from the NCBI database are: bubaline herpesvirus 1
(BuHV-1)[MSRSLLVALATAALLAMVRGLDPLLDAMRREE
AMDFWSAGCYARGVPLSEPPQAMVVFYAALTVVMLAV-
ALYAYGLCFRLMSAGGPNKKEVRGRG; FAMR, unpub-
lished], canid herpesvirus (CHV) [patent EPO910406 http://ep.
espacenet.com ], cervid herpesvirus 1 (CvHV-1) [MARMPRS-
LLSALAVAALLAIAGARDPLLDAMRHEGAMDFWSASCY-
ARGVPL SEPPQALVVFYVALAVVMFSVAVYAYGLCLRL-
VGADSPNKKDSRGRG; FAMR, unpublished].
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